Benzinga · Aug 10, 2026
Canaccord Genuity Maintains Buy on Orthofix Medical, Lowers Price Target to $13
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
NASDAQ · OFIX
Healthcare · Medical - Devices
$8.91
Down-$0.22 (-2.47%)
Updated Sep 10, 2026, 11:02 PM
SID Score
3.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
OFIX closed at $8.91 after 20 trading sessions, down 14.33% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $9.13 | $9.2097 | $8.83 | $8.91 | 565.53K |
| Sep 8, 2026 | $9.17 | $9.26 | $8.97 | $9.15 | 322.64K |
| Sep 4, 2026 | $9.22 | $9.36 | $9.15 | $9.29 | 202.59K |
| Sep 3, 2026 | $9.50 | $9.50 | $8.96 | $9.31 | 335.73K |
| Sep 2, 2026 | $9.40 | $9.60 | $9.29 | $9.38 | 330.41K |
| Sep 1, 2026 | $9.39 | $9.64 | $9.32 | $9.43 | 491.16K |
| Aug 31, 2026 | $9.57 | $9.60 | $9.32 | $9.39 | 334.69K |
| Aug 28, 2026 | $9.64 | $9.81 | $9.61 | $9.70 | 221.25K |
| Aug 27, 2026 | $9.66 | $9.86 | $9.56 | $9.63 | 204.69K |
| Aug 26, 2026 | $9.64 | $9.82 | $9.44 | $9.75 | 246.1K |
| Aug 25, 2026 | $9.78 | $9.78 | $9.52 | $9.64 | 283.01K |
| Aug 24, 2026 | $10.03 | $10.21 | $9.71 | $9.79 | 265.42K |
| Aug 21, 2026 | $10.02 | $10.07 | $9.78 | $10.01 | 415.38K |
| Aug 20, 2026 | $10.33 | $10.52 | $9.98 | $10.01 | 225.28K |
| Aug 19, 2026 | $10.24 | $10.7441 | $10.24 | $10.48 | 204.01K |
| Aug 18, 2026 | $10.09 | $10.42 | $10.09 | $10.22 | 234.06K |
| Aug 17, 2026 | $10.18 | $10.23 | $9.96 | $10.03 | 233.39K |
| Aug 14, 2026 | $10.13 | $10.435 | $10.13 | $10.34 | 273.4K |
| Aug 13, 2026 | $10.43 | $10.53 | $10.16 | $10.18 | 244.7K |
| Aug 12, 2026 | $10.49 | $10.61 | $9.96 | $10.40 | 333.04K |
The latest Smart Investors Daily articles mentioning OFIX.
OFIX research
Company profile and research snapshot.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Buy | — |
| Jul 6, 2026 | Barrington Research | Outperform | — |
| May 22, 2026 | Canaccord Genuity | Buy | — |
| May 22, 2026 | Stifel | Buy | — |
| May 22, 2026 | Barrington Research | Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $18 to $13.
ChartMill · Aug 5, 2026
Orthofix Medical (OFIX) beats Q2 profit estimates, raises full-year 2026 guidance; stock up ~9.6% premarket despite in-line revenue.
SeekingAlpha · Aug 5, 2026
Orthofix Medical Inc. (OFIX) Q2 2026 Earnings Call August 5, 2026 8:30 AM EDTCompany ParticipantsJulie Dewey - Chief Investor Relations & Communications...
SeekingAlpha · Aug 5, 2026
2026-08-05. The following slide deck was published by Orthofix Medical Inc.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OFIX.